Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection

YX Du, XP Chen - Clinical Pharmacology & Therapeutics, 2020 - Wiley Online Library
An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …
被引用次数：498 相关文章

Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection.

YX Du, XP Chen - 2020 - cabidigitallibrary.org
An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID-2019. In addition to the recommended …

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection

YX Du, XP Chen - Clinical pharmacology and …, 2020 - pubmed.ncbi.nlm.nih.gov
An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID-2019. In addition to the recommended …

[引用][C] Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

YX Du, XP Chen - Clinical Pharmacology & Therapeutics, 2020 - cir.nii.ac.jp
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学 …

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.

YX Du, XP Chen - Clinical Pharmacology and Therapeutics, 2020 - europepmc.org
An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID-2019. In addition to the recommended …